HYPR trades 0.0% below Wall Street's consensus target of $1.60.
Last 12 months price action with 12-month analyst target path
The base valuation assumes HYPR achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Hyperfine, Inc. (HYPR) has a Wall Street consensus price target of $1.60, based on estimates from 4 covering analysts. With the stock currently trading at $1.49, this represents a potential upside of +0.0%. The company has a market capitalization of $125M.
Analyst price targets range from a low of $1.60 to a high of $1.60, representing a 0% spread in expectations. The median target of $1.60 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, HYPR trades at a trailing P/E of -3.5x. Analysts expect EPS to grow +2.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
PRCTPROCEPT BioRobotics Corporation | $1.2B | $21.06 | $32.00 | +47.3% | Buy | — | 15 |
NVCRNovoCure Limited | $1.5B | $13.61 | $33.00 | +131.1% | Buy | — | 15 |
INVAInnoviva, Inc. | $1.7B | $22.67 | $37.00 | +64.5% | Buy | 6.3x | 10 |
AEYEAudioEye, Inc. | $76M | $6.08 | — | — | — | — | — |
GEHCGE HealthCare Technologies Inc. | $27.6B | $60.64 | $81.10 | +31.7% | Buy | 12.6x | 18 |
SYKStryker Corporation | $116.7B | $304.64 | $387.46 | +25.9% | Buy | 20.5x | 51 |
IRTCiRhythm Technologies, Inc. | $3.4B | $104.69 | $188.75 | +80.4% | Buy | — | 20 |
INSPInspire Medical Systems, Inc. | $1.2B | $41.35 | $57.36 | +34.6% | Hold | 47.5x | 27 |
NVDANVIDIA Corporation | $5.1T | $208.66 | $316.79 | +50.4% | Buy | 23.6x | 79 |
MSFTMicrosoft Corporation | $2.7T | $367.34 | $551.96 | +45.5% | Buy | 22.6x | 82 |
Quick answers to the most common questions about buying HYPR stock.
The consensus price target for HYPR is $1.6, close to the current price of $1.49 (0.0% implied move). Based on 4 analyst estimates, the stock appears fairly valued near current levels.
HYPR has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $1.6 implies 0.0% upside from current levels.
HYPR's current price is $1.49 with a consensus target of $1.6 (0.0% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $1.6 for HYPR, while the most conservative target is $1.6. The consensus of $1.6 represents the median expectation. These targets typically reflect 12-month expectations.
HYPR is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HYPR stock forecast based on 4 Wall Street analysts shows a consensus price target of $1.6, with estimates ranging from $1.6 (bear case) to $1.6 (bull case). The median consensus rating is "Buy".
HYPR appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $1.6 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HYPR analyst price targets range from $1.6 to $1.6, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $1.6 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.